ProPhase Labs Inc (PRPH) is around the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. PRPH received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. ProPhase Labs Inc also achieved a score of 95 in the Drug Manufacturers - Specialty & Generic industry, putting it above 95 percent of Drug Manufacturers - Specialty & Generic stocks. Drug Manufacturers - Specialty & Generic is ranked 142 out of the 148 industries.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 62 would rank higher than 62 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With ProPhase Labs Inc Stock Today?
ProPhase Labs Inc (PRPH) stock is trading at $5.89 as of 9:54 AM on Friday, Jun 11, an increase of $0.30, or 5.37% from the previous closing price of $5.59. The stock has traded between $5.77 and $6.11 so far today. Volume today is less active than usual. So far 84,975 shares have traded compared to average volume of 408,007 shares.